MICHAEL JOHN SOLON: Open Payments
NPI 1295478337 · EDINBURG, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,524 in 148 payments from 15 companies in 2025. Trend: 2023 $1,282 · 2024 $3,928 · 2025 $4,524
Food & beverage: $4,524
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 14 | $670 |
| Alkermes, Inc. | 20 | $642 |
| Teva Pharmaceuticals USA, Inc. | 21 | $595 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $561 |
| ABBVIE INC. | 20 | $462 |
| Supernus Pharmaceuticals, Inc. | 24 | $440 |
| E.R. Squibb & Sons, L.L.C. | 7 | $290 |
| Collegium Pharmaceutical, Inc. | 8 | $225 |
| Corium, LLC | 10 | $173 |
| Melinta Therapeutics, LLC | 1 | $125 |
Products named: CAPLYTA, REXULTI, VRAYLAR, Qelbree, ARISTADA, UZEDY, COBENFY, LYBALVI.
Industry payments across TX — which companies pay providers there.
